-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Palvella Therapeutics, Raises Price Target to $243

Benzinga·11/09/2026 18:15:03
Canaccord Genuity analyst Whitney Ijem maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $232 to $243.